This clinical trial is focused on boys with a condition known as short predicted height, which means they are expected to be shorter than average when they grow up. The study is examining the effects of two treatments: Omnitrope, which is a form of growth hormone, and Letrozole, an aromatase inhibitor. Aromatase inhibitors are medications that can help increase height by affecting hormone levels during puberty.

The purpose of the study is to see if boys who receive a combination of both Omnitrope and Letrozole during puberty will grow taller than those who receive only Omnitrope. The study will last for four years, during which participants will receive their assigned treatment. The growth of the boys will be monitored to determine if the combination therapy leads to a greater increase in height compared to the growth hormone alone.

Participants in the study will receive their treatments either as a solution for injection in the case of Omnitrope or as film-coated tablets for Letrozole. The study aims to provide valuable information on the effectiveness and safety of these treatments in helping boys with short predicted height achieve a taller adult height.